Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Net Cash Flow for 9 consecutive years, with $114.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 35.62% to $114.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.9 million, a 33.35% decrease, with the full-year FY2025 number at $31.9 million, down 33.35% from a year prior.
  • Net Cash Flow was $114.4 million for Q4 2025 at Denali Therapeutics, up from -$50.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $114.4 million in Q4 2025 to a low of -$188.5 million in Q1 2022.
  • A 5-year average of -$15.0 million and a median of -$3.4 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: surged 503.37% in 2024, then plummeted 414.87% in 2025.
  • Denali Therapeutics' Net Cash Flow stood at -$101.1 million in 2021, then skyrocketed by 198.37% to $99.4 million in 2022, then tumbled by 121.03% to -$20.9 million in 2023, then soared by 503.37% to $84.3 million in 2024, then surged by 35.62% to $114.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Net Cash Flow are $114.4 million (Q4 2025), -$50.2 million (Q3 2025), and $84.3 million (Q2 2025).